P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE...

por Jurczak, Wojciech, Ghesquieres, Herve, Karimi, Yasmin, Cheah, Chan, Roost Clausen, Michael, Cunningham, David, Rok Do, Young, Lewis, David, Gasiorowski, Robin, Min Kim, Tae, Poel, Marjolein Van Der, Limei Poon, Michelle, Feldman, Tatyana, Linton, Kim, Sureda, Anna, Hutchings, Martin, Kanoun, Salim, Vercellino, Laetitia, Cota Stirner, Mariana, Mcgoldrick, Stephanie, Liu, Yan, Sacchi, Mariana, Lugtenburg, Pieternella, Thieblemont, Catherine
Publicado 2023

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

por Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, Lugtenburg, Pieternella J.
Publicado 2023